DX1002 / Guangzhou Anhao Pharma - LARVOL DELTA

First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors. (PubMed, Cell Rep Med) - P1 | "In conclusion, DX1002 is well tolerated and exhibits preliminary anti-tumor efficacy in patients with solid tumors. This study was registered at chictr.org.cn (ChiCTR2400080298)."

Journal • P1 data • Colon Cancer • Colorectal Cancer • Fatigue • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A phase Ib/IIa study of DX1002, a novel drug in patients with pretreated advanced hepatocellular carcinoma: Efficacy and safety analysis. (ASCO 2024) - "Initial data shows DX1002 demonstrated manageable safety profile and promising anti-tumor potential in pre-treated advanced hepatocellular carcinoma. Further exploration of DX1002 in HCC is warranted."

Clinical • Metastases • P1/2 data • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Renal Disease • Solid Tumor